Physician profile
Michael Levine
NPI 1003948464
$267,283.29
in general payments reported to CMS, 2019-2025
29 companies · $311 in 2025
The $311 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $64K · 2020: $1,860 · 2021: $44K · 2022: $55K · 2023: $60K · 2024: $41K · 2025: $311.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $97K · Food and Beverage: $4,126.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $96,976.00 |
| Food and Beverage | $4,125.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $262,965.75 | 2019-2024 | Xarelto |
| Amgen INC. | $903.94 | 2019-2024 | Repatha |
| Kowa Pharmaceuticals America, INC. | $556.12 | 2019-2023 | Livalo |
| Amarin Pharma, INC. | $354.71 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $303.63 | 2019-2020 | |
| Boston Scientific Corporation | $271.90 | 2019-2024 | Watchman Flx |
| Sanofi-Aventis U.S. LLC | $268.81 | 2019 | |
| Vifor Pharma, INC. | $195.29 | 2019-2025 | Veltassa |
| Novartis Pharmaceuticals Corporation | $166.07 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $152.53 | 2019-2025 | Camzyos |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $146.79 | 2025 | Lifevest |
| Medtronic USA, INC. | $144.21 | 2020 | |
| Astellas Pharma US INC | $108.46 | 2021-2022 | |
| Medtronic Vascular, INC. | $106.38 | 2019 | |
| Tepha INC | $84.03 | 2019 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $75.52 | 2019 | |
| Inspire Medical Systems, INC. | $72.00 | 2023-2024 | Inspire |
| Azurity Pharmaceuticals, INC. | $67.99 | 2023-2024 | Edarbyclor, Edarbi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $65.34 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $47.26 | 2019 | |
| Gilead Sciences, INC. | $44.35 | 2019 | |
| Cumberland Pharmaceuticals, INC. | $35.76 | 2024-2025 | Caldolor |
| Accord Healthcare, INC. | $33.22 | 2022-2023 | |
| Abbott Laboratories | $26.90 | 2019 | |
| Clarus Therapeutics INC. | $21.21 | 2021 | |
| Janssen Biotech, INC. | $19.80 | 2021 | |
| Eisai INC. | $19.60 | 2019 | |
| Esperion Therapeutics, INC. | $14.00 | 2021 | |
| Paratek Pharmaceuticals, INC. | $11.72 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Levine listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.